Davenport MS, Montgomery JS, Kunju LP, et al. - This prospective single-arm clinical trial was designed to investigate whether ¹⁸F-choline PET/mpMRI can improve the specificity of multiparametric MRI (mpMRI) of the prostate for Gleason ≥ 3+4 prostate cancer. Researchers conducted mpMRI and ¹⁸F-choline PET/CT on 56 evaluable participants with 90 Likert score 3–5 mpMRI target lesions, using a ¹⁸F-choline target-to-background ratio of greater than 1.58 to indicate a positive ¹⁸F-choline result before the targeted and systematic prostate biopsy. They carried out prostate biopsies after registration of real-time transrectal ultrasound with T2-weighted MRI. The results of the study indicated that, compared with mpMRI, ¹⁸F-choline PET/mpMRI was found to improve the identification of Gleason ≥ 3+4 prostate cancer, with the principal effect being improved risk stratification of intermediate-risk mpMRI lesions.